Detection and identification of cytochrome P-450 2C9 alleles *1, *2, and *3 by high-resolution melting curve analysis of PCR amplicons

American Journal of Clinical Pathology

Volumn 125, Issue 4, 2006, Pages 584-591

  Hill, Charles E ^a,b   Duncan, Alexander ^a   Wirth, Diane ^a   Nolte, Frederick S ^a  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b EMORY UNIVERSITY HOSPITAL   (United States)

Author keywords

Anticoagulation; Genotyping; Melting analysis; P 450; PCR; Pharmacogenomics; Polymerase chain reaction; Warfarin

Indexed keywords

CYTOCHROME P450 2C9; DYE; WARFARIN;

ACCURACY; ADULT; AGED; ALLELE; AMPLICON; ANALYTIC METHOD; ANTICOAGULATION; ARTICLE; CONTROLLED STUDY; DNA BINDING; DNA PROBE; DRUG METABOLISM; EXON; FEMALE; FLUORESCENCE; GENE AMPLIFICATION; GENE IDENTIFICATION; GENE SEQUENCE; GENOTYPE; HETEROZYGOTE; HIGH RESOLUTION MELTING CURVE ANALYSIS; HUMAN; MAJOR CLINICAL STUDY; MALE; MELTING POINT; PHARMACOGENOMICS; PHASE TRANSITION; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; SEQUENCE ANALYSIS; SINGLE NUCLEOTIDE POLYMORPHISM; STATISTICAL SIGNIFICANCE; TEMPERATURE DEPENDENCE; WILD TYPE;

EID: 33645542946     PISSN: 00029173     EISSN: None     Source Type: Journal    
DOI: 10.1309/76QPHQ892F17QKNC     Document Type: Article

References (17)

1. Lee CR, Goldstein JA, Pieper JA. Cytochrome P450 2C9 polymorphisms: a comprehensive review of the in-vitro and human data. Pharmacogenetics. 2002;12:251-263.
2. Human Cytochrome P450 Allele Nomenclature Committee. Inclusion criteria. Available at www.imm.ki.se/CYPalleles/criteria.htm. Accessed July 2005.
3. Kidd RS, Curry TB, Gallagher S, et al. Identification of a null allele of CYP2C9 in an African-American exhibiting toxicity to phenytoin. Pharmacogenetics. 2001;11:803-808.
4. Higashi MK, Veenstra DL, Kondo LM, et al. Association between CYP2C9 genetic variants and anticoagulation-related outcomes during warfarin therapy. JAMA. 2002;287:1690-1698.
5. Linder MW, Looney S, Adams JE III, et al. Warfarin dose adjustments based on CYP2C9 genetic polymorphisms. J Thromb Thrombolysis. 2002;14:227-232.
6. Sullivan-Klose TH, Ghanayem BI, Bell DA, et al. The role of the CYP2C9-Leu359 allelic variant in the tolbutamide polymorphism. Pharmacogenetics. 1996;6:341-349.
7. Wang SL, Huang J, Lai MD, et al. Detection of CYP2C9 polymorphism based on the polymerase chain reaction in Chinese. Pharmacogenetics. 1995;5:37-42.
8. Yasar U, Eliasson E, Dahl ML, et al. Validation of methods for CYP2C9 genotyping: frequencies of mutant alleles in a Swedish population. Biochem Biophys Res Commun. 1999;254:628-631.
9. Ririe K, Rasmussen RP, Wittwer CT. Product differentiation by analysis of DNA melting curves during the polymerase chain reaction. Anal Biochem. 1997;245:154-160.
10. Lay MJ, Wittwer CT. Real-time fluorescence genotyping of factor V Leiden during rapid cycle PCR. Clin Chem. 1997;43:2262-2267.
11. Gundry CN, Vandersteen JG, Reed GH, et al. Amplicon melting analysis with labeled primers: a closed-tube method for differentiating homozygotes and heterozygotes. Clin Chem. 2003;49:396-406.
12. Liew M, Pryor R, Palais R, et al. Genotyping of single-nucleotide polymorphisms by high-resolution melting of small amplicons. Clin Chem. 2004;50:1156-1164.
13. Reed GH, Wittwer CT. Sensitivity and specificity of single-nucleotide polymorphism scanning by high-resolution melting analysis. Clin Chem. 2004;50:1748-1754.
14. Wittwer CT, Reed GH, Gundry CN, et al. High-resolution genotyping by amplicon melting analysis using LCGreen. Clin Chem. 2003;49:853-860.
15. Nasu K, Kubota T, Ishizaki T. Genetic analysis of CYP2C9 polymorphism in a Japanese population. Pharmacogenetics. 1997;7:405-409.
16. Schutz E, von Ahsen N. Spreadsheet software for thermodynamic melting point prediction of oligonucleotide hybridization with and without mismatches. Biotechniques. 1999;27:1218-1222.
17. Makris M, Watson HG. The management of coumarin-induced over-anticoagulation. Br J Haematol. 2001;114:271-280.